Aboutme.Profsubin: Short ABBV As It has Already Reached The Target of $100

 Aboutme.Profsubin: Short ABBV As It has Already Reached The Target of $100

After Gaining 33% in 60 Days, AbbVie Beats Third-Quarter Earnings  Expectations (NYSE:ABBV) | Stock Investor

1. AbbVie is a bio-pharma company founded due to spin-off of Abbot lab.

2. Abbot lab will be specialising in medical devices, equipment for diagnosis, and nutrition products.

3. ABBV will be doing research & development in pharma manufacturing.

4. Listed in NYSE stock exchange.

5. Abbot Lab and ABBV are valued separately.

6. Initially it was having a report that expiry of patent will tend the slowdown in drug division, assumed.

7. If the share drops down to $86.23, then the share will go down.

8. The next target we expect is $81 -$82/share.

9. Revenue is $33.26 Billion.

10. Operating income in 2018 is $6.383 Billion.

11. Net Income is $5.687 Billion.

12. Total Assets is $59.352 Billion.

13. Total Equity is $8.446 Billion.

14. Number of employees is 30000.

15. For best advice on Shares:

Contact; +91 7000 188 030

or Like My Page On Quora: Prof Subin




According to Miles White, CEO at the time, the purpose of the split was to allow markets to value the two businesses separately; White said that investors would "benefit from two fundamentally different investment opportunities with distinct strategic profiles and business priorities."[5] Some investors were concerned that the split was done to protect the value of the device business from the loss of value facing the drug division due to the imminent expiration of patents on Humira, which accounted for about half of the drug division's revenue.[5]

As of December 2015, the company employed in excess of 28,000 globally, and provided products to individuals in mor

Comments

Popular posts from this blog

Shannon V/s Seema Love Affair

Aboutme.Subinfinance - Greece Made Europe Bleed With A "No" Referendum

Buy Silver At $23.279